Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg raises target price on JD Sports

(Sharecast News) - Analysts at Berenberg hiked their target price on sportswear retailer JD Sports from 128p to 155p on Thursday, stating it played "an important role in the market". Berenberg said JD Sports' recently released Q2 trading was in line with consensus expectations, with the 3.0% fall in like-for-like sales reflecting "the relatively tough prior year comparative", due to the UEFA Euro football competition and Paris Olympics, which both took place in summer 2024.

The German bank, which has a 'buy' rating on the stock, stated that, as the leading sportswear distributor globally, with 80% of sales accounted for by physical stores, JD Sports provides hundreds of external sporting goods brands with "an important route to market", particularly via physical stores. As such, Berenberg said it fulfils a function that was "unmet by online marketplaces and the brands' own direct-to-consumer online operations".

Berenberg highlighted that JD has long-established relationships with many of the brands it stocks, with half of its apparel sales and 30% of its footwear sales relating to exclusive lines. It also noted that JD does not consider the direct impact of Donald Trump's ongoing tariff wars to be material, even if indirect effects remain uncertain.

"Factoring in a £14m FX hit in H1 and taking a slightly more cautious approach to our sales estimates, we reduce our current year adjusted PBT estimate by 3%, from £901m to £872m. Our outer-year profit estimates fall due to the lower base. Our DCF valuation has been reduced along with our profit estimates, from 196p to 155p, but we now move our previously cautious price target of 128p upwards. This is now in line with our DCF valuation, at 155p," said Berenberg.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.